Top 5 Highlights From the 2016 ASCO GI Cancers Symposium

Evofosfamide Fails to Show Overall Survival Benefit in Pancreatic Cancer:

Adding evofosfamide to gemcitabine in patients with metastatic pancreatic cancer failed to show an overall survival advantage, according to results from the phase III MAESTRO trial, presented by Eric Van Cutsem, MD, PhD, professor of internal medicine at the University of Leuven in Belgium (abstract 193). This combination had previously shown an improved progression-free survival in a phase II trial. The experimental combination failed to show a statistically significant overall survival improvement over gemcitabine alone (8.7 vs 7.6 months,

P

= .0589). Photo © ASCO/Todd Buchanan 2016.

Treatment at High-Volume Center Improved Pancreatic Cancer Survival:

Patients with pancreatic cancer who received adjuvant chemotherapy at a high-volume center had superior median and 5-year overall survival compared with patients who were treated in a community setting, according to the results of a study presented by Margaret T Mandelson, PhD, MPH, of the Floyd & Delores Jones Cancer Institute at Virginia Mason in Seattle (abstract 191). Study results showed that a highly select group of patients with localized pancreatic cancer who underwent successful surgical resection at a high-volume institution had significantly longer overall survival (44 vs 28 months;

P

P

Long-Term Results Support Chemoradiotherapy in Esophageal Cancer:

Mature data from the SCOPE 1 trial, a randomized phase II/III trial comparing definitive chemoradiotherapy plus or minus cetuximab in patients with esophageal cancer, showed unprecedented survival in the chemoradiotherapy alone arm, with rates comparable to surgical trials in this patient population (abstract 118). Results of the trial were presented by Somnath Mukherjee, MD, of the Gray Institute for Radiation Oncology and Biology, University of Oxford, United Kingdom. Patients in the trial treated with cetuximab had a lower median overall survival rate (24.7 vs 34.5 months in patients treated with chemoradiotherapy; hazard ratio, 1.25;

P

= .137), though the authors attributed this to lower radiotherapy compliance in the cetuximab arm of the trial (78% vs 90%). The 3-year overall survival rate (47.2%) in the chemoradiotherapy arm is comparable to published surgical trials. Photo © ASCO/Todd Buchanan 2016.

Lutathera Slows Disease Progression in Midgut Neuroendocrine Tumors:

A novel drug,

¹⁷⁷

Lutetium-DOTATATE (Lutathera), significantly lowered the risk for disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumors, according to the phase III results of the NETTER-1 trial. Compared with patients treated with octreotide LAR 60 mg, treatment with

¹⁷⁷

Lutetium-DOTATATE resulted in about an 80% decreased risk for progression or death, according to data presented by Jonathan R. Strosberg, MD, a medical oncologist at the Moffitt Cancer Center in Tampa, Florida. Median progression-free survival, the trial’s primary endpoint, was not yet reached among patients assigned the novel therapy compared with 8.4 months among patients assigned octreotide LAR (95% CI, 5.8–11 months;

P

177Lutetium-DOTATATE (HR, 0.21; 95% CI, 0.13–0.34). Photo © ASCO/Todd Buchanan 2016.